STOCK TITAN

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)

Kazia Therapeutics (NASDAQ: KZIA) has secured a Type C meeting with the FDA in December 2024 to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma multiforme (GBM). The meeting follows promising Phase II/III GBM-AGILE trial results announced in July 2024, where paxalisib showed meaningful improvement in overall survival for newly diagnosed unmethylated GBM patients. The drug has previously received both orphan drug and fast track designations from FDA. The company has updated its corporate presentation with preliminary GBM AGILE trial data and announced participation in upcoming medical conferences, including the Society for Neuro-Oncology Annual Meeting and San Antonio Breast Cancer Symposium.

Kazia Therapeutics (NASDAQ: KZIA) ha ottenuto un incontro di Tipo C con la FDA previsto per dicembre 2024 per discutere i potenziali percorsi di registrazione per paxalisib nel trattamento del glioblastoma multiforme (GBM) recentemente diagnosticato. L'incontro segue i risultati promettenti dello studio clinico di fase II/III GBM-AGILE annunciati a luglio 2024, nei quali paxalisib ha mostrato un significativo miglioramento della sopravvivenza globale per i pazienti con GBM non metilato appena diagnosticato. Il farmaco ha già ricevuto le designazioni di farmaco orfano e fast track dalla FDA. L'azienda ha aggiornato la sua presentazione aziendale con dati preliminari dello studio GBM AGILE e ha annunciato la sua partecipazione a prossimi congressi medici, inclusi l'Annual Meeting della Society for Neuro-Oncology e il San Antonio Breast Cancer Symposium.

Kazia Therapeutics (NASDAQ: KZIA) ha conseguido una reunión de tipo C con la FDA en diciembre de 2024 para discutir posibles vías de registro para paxalisib en glioblastoma multiforme (GBM) recién diagnosticado. La reunión sigue a los prometedores resultados de los ensayos de fase II/III de GBM-AGILE anunciados en julio de 2024, donde paxalisib mostró una mejora significativa en la supervivencia general para pacientes con GBM no metilados recién diagnosticados. El fármaco ya había recibido las designaciones de medicamento huérfano y vía rápida por parte de la FDA. La empresa ha actualizado su presentación corporativa con datos preliminares del ensayo GBM AGILE y ha anunciado su participación en próximas conferencias médicas, incluyendo la Reunión Anual de la Society for Neuro-Oncology y el Simposio sobre Cáncer de Mama de San Antonio.

Kazia Therapeutics (NASDAQ: KZIA)는 2024년 12월 FDA와의 C형 회의를 확보하여 paxalisib의 새롭게 진단된 다형성 교모세포종(GBM) 등록 경로에 대해 논의할 예정입니다. 이 회의는 2024년 7월 발표된 GBM-AGILE 2/3상 시험의 유망한 결과를 기반으로 하며, paxalisib은 새롭게 진단된 비 메틸화 GBM 환자에서 전체 생존율의 의미 있는 개선을 보여주었습니다. 이 약물은 이전에 FDA로부터 고아약 및 신속 심사 지정도 받았습니다. 회사는 GBM AGILE 시험의 초기 데이터를 포함한 기업 발표를 업데이트하고, Neuro-Oncology 연례 회의와 San Antonio Breast Cancer Symposium을 포함한 향후 의료 회의에 참가할 것이라고 발표했습니다.

Kazia Therapeutics (NASDAQ: KZIA) a obtenu une réunion de type C avec la FDA prévue en décembre 2024 pour discuter des voies potentielles d'enregistrement pour paxalisib dans le glioblastome multiforme (GBM) récemment diagnostiqué. Cette réunion fait suite à des résultats prometteurs de l'essai de phase II/III GBM-AGILE annoncés en juillet 2024, où paxalisib a montré une amélioration significative de la survie globale chez les patients nouvellement diagnostiqués avec un GBM non méthylé. Le médicament a déjà reçu les désignations de médicament orphelin et de voie rapide de la part de la FDA. L'entreprise a mis à jour sa présentation d'entreprise avec des données préliminaires de l'essai GBM AGILE et a annoncé sa participation à des conférences médicales à venir, y compris la réunion annuelle de la Society for Neuro-Oncology et le Symposium sur le cancer du sein de San Antonio.

Kazia Therapeutics (NASDAQ: KZIA) hat ein Typ-C-Meeting mit der FDA für Dezember 2024 gesichert, um mögliche Zulassungswege für paxalisib bei neu diagnostiziertem Glioblastom multiforme (GBM) zu erörtern. Das Meeting folgt auf vielversprechende Ergebnisse der Phase-II/III-Studie GBM-AGILE, die im Juli 2024 bekannt gegeben wurden, bei der paxalisib eine signifikante Verbesserung des Gesamtüberlebens bei neu diagnostizierten nicht methylierten GBM-Patienten zeigte. Das Medikament erhielt zuvor sowohl die Orphan-Drug- als auch die Fast-Track-Beantragung von der FDA. Das Unternehmen hat seine Unternehmenspräsentation mit vorläufigen Daten der GBM AGILE-Studie aktualisiert und die Teilnahme an bevorstehenden medizinischen Konferenzen, einschließlich des Kongresses der Society for Neuro-Oncology und des San Antonio Breast Cancer Symposium, angekündigt.

Positive
  • FDA granted Type C meeting to discuss registration pathway for paxalisib
  • Positive Phase II/III trial results showing meaningful survival improvement
  • Drug holds both orphan drug and fast track FDA designations for GBM
Negative
  • None.

Insights

The FDA granting a Type C meeting to discuss potential registration pathways for paxalisib in newly diagnosed glioblastoma represents a important regulatory milestone. The meeting follows promising Phase II/III GBM-AGILE trial results showing meaningful survival improvements in unmethylated GBM patients. This is particularly significant given paxalisib's existing orphan drug and fast track designations.

The blood-brain barrier penetrant PI3K/mTOR inhibitor addresses a critical unmet need in GBM treatment, where current options are The December meeting could potentially accelerate paxalisib's path to market, especially if the full secondary endpoint data expected later this year continues to show strong efficacy signals.

For a small-cap company ($18.3M), securing this FDA interaction is strategically important and could lead to clearer development guidelines or potentially expedited review pathways. The combination of positive trial data and regulatory engagement strengthens Kazia's position in the competitive oncology space.

Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM)

Company updates to corporate presentation and participation in upcoming medical meetings

SYDNEY, Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM.

In July 2024, the Company announced results from the Phase II/III clinical trial, GBM-AGILE, in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed clinically meaningful improvement in a prespecified secondary analysis for overall survival. Full data including secondary endpoints from the paxalisib arm of the GBM-AGILE study is expected to be presented at a scientific meeting later this year.

Paxalisib has previously received orphan drug designation and fast track designation from the FDA for glioblastoma in unmethylated MGMT promoter status patients, following radiation plus temozolomide therapy. 

Updated corporate presentation
Today, the Company also announced that it has updated its corporate presentation, which now incorporates preliminary data from the GBM AGILE Phase II/III clinical trial evaluating paxalisib versus the standard of care for the treatment of in patients with glioblastoma. The updated presentation can be found at https://www.kaziatherapeutics.com/site/pdf/ebcc5b2e-29a6-410c-ab9a-c3e722413615/Kazia-Corporate-Presentation-November-2024.pdf

Participation in Upcoming and Recent Medical and Investor Conferences

The company plans on attending the following medical conferences in the fourth quarter of 2024:

  • Society for Neuro-Oncology 29th Annual Meeting and Education Day, November 21-24, 2024, in Houston, TX
  • San Antonio Breast Cancer Symposium, December 10-13, 2024, in San Antonio, TX

These events provide Kazia with the opportunity to engage with key stakeholders and share the Company's vision to make a difference in the lives of patients by developing innovative cancer treatments. Kazia looks forward to meeting with investors in person at these events and invites discussion regarding partnering and investment opportunities.

Over the last several months, the Company has also participated and presented at a number of medical and investor conferences, including:

  • H C Wainwright 26th Annual Global Investment Conference from Sep. 9-11, 2024
  • 15th Biennial AACR Ovarian Cancer Research Symposium, Sep. 20 – 21, 2024
  • Oppenheimer Oncology Summit, in collaboration with MD Anderson Cancer Center, Sep. 26, 2024
  • American Society for Radiation Oncology Annual Meeting, Sep. 29 – Oct. 1, 2024
  • Deerfield CEO Conference, Oct. 8-9, 2024
  • Maxim Group's 2024 Healthcare Virtual Summit, Fireside Chat, Oct. 15, 2024

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major medical conference. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

This announcement was authorized for release by Dr John Friend, CEO.

 

Cision View original content:https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-granting-of-type-c-meeting-with-fda-to-discuss-potential-next-steps-for-paxalisib-in-the-treatment-of-newly-diagnosed-glioblastoma-multiforme-302295073.html

SOURCE Kazia Therapeutics Limited

FAQ

What is the purpose of Kazia Therapeutics' (KZIA) FDA Type C meeting in December 2024?

The Type C meeting with FDA is to discuss potential pathways for registering paxalisib for the treatment of newly diagnosed glioblastoma multiforme (GBM).

What were the results of KZIA's Phase II/III GBM-AGILE trial announced in July 2024?

The trial showed clinically meaningful improvement in overall survival for newly diagnosed unmethylated GBM patients treated with paxalisib in a prespecified secondary analysis.

What regulatory designations has KZIA's paxalisib received from the FDA?

Paxalisib has received both orphan drug designation and fast track designation from the FDA for glioblastoma in unmethylated MGMT promoter status patients.

Kazia Therapeutics Limited American Depositary Shares

NASDAQ:KZIA

KZIA Rankings

KZIA Latest News

KZIA Stock Data

18.74M
33.29M
5.98%
0.49%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW SOUTH WALES 2113